Evaluation of a Dermocosmetic Serum for Managing Hyperpigmentation Disorders in Phototypes IV ‐ VI Individuals From South Africa and Argentina
Open Access
- 29 May 2026
- journal article
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (6)
Abstract
Background: Hyperpigmentation disorders are a distressing condition, especially for individuals with skin of color who are at higher risk. Often treated topically, a significant advancement in this field was Kligman's depigmenting trio, inhibiting melanogenesis, providing anti‐inflammatory benefits, and promoting epidermal renewal. Aims: Evaluate a serum (Pigmentbio C‐Concentrate, NAOS, LABORATOIRE BIODERMA), inspired by Kligman's trio's mode of action. Methods: Clinical studies were conducted on phototype IV–VI subjects in South Africa and Argentina. Subjects applied the serum nightly for 84 days. Clinical assessments were performed on days 0, 28, 56, and 84, with instrumental skin color evaluation in Argentina. The burden of hyperpigmentation was assessed at baseline and D84 using the Dermatology Life Quality Index (DLQI, South Africa) or the Melasma Quality of Life Questionnaire (MELASQoL, Argentina). Results: In South Africa, clinical assessments showed a significant reduction in the number (−15%), intensity (−32%), and size (−13%) of hyperpigmented elements within 28 days. The Argentinian study similarly reported significantly decreased intensity (−18%), visibility (−32%), and contrast (−29%) of hyperpigmented elements on D28, alongside improved complexion homogeneity (+17%). In both studies, maximum improvements occurred on D84. These results were supported by instrumental assessments of skin luminance and pigmentation of hyperpigmented areas (L*: +5%, ITA°: +53% on D84), and color difference between hyperpigmented and non‐hyperpigmented areas (∆E: −16% on D84). Participants also reported a reduced burden of hyperpigmentation (DLQI: −92%; MELASQoL: −33%). Conclusion: Replicating the complementary activities of Kligman's trio, the serum effectively reduces hyperpigmentation and its associated burden in individuals with darker phototypes.Keywords
This publication has 20 references indexed in Scilit:
- Disorders of Facial HyperpigmentationDermatologic Clinics, 2023
- Self-applied topical interventions for melasma: a systematic review and meta-analysis of data from randomized, investigator-blinded clinical trialsBritish Journal of Dermatology, 2022
- Disorders of hyperpigmentation. Part II. Review of management and treatment options for hyperpigmentationJournal of the American Academy of Dermatology, 2022
- Andrographis paniculata (Burm.f.) Nees: Traditional uses, phytochemistry, pharmacological properties and quality control/quality assuranceJournal of Ethnopharmacology, 2021
- Chemical peels: A review of current practiceAustralasian Journal of Dermatology, 2017
- Postinflammatory hyperpigmentation: A comprehensive overviewJournal of the American Academy of Dermatology, 2017
- Andrographolide inhibits hypoxia-induced HIF-1α-driven endothelin 1 secretion by activating Nrf2/HO-1 and promoting the expression of prolyl hydroxylases 2/3 in human endothelial cellsEnvironmental Toxicology, 2016
- Andrographolide suppresses melanin synthesis through Akt/GSK3β/β-catenin signal pathwayJournal of Dermatological Science, 2015
- Environment‐induced lentigines: formation of solar lentigines beyond ultraviolet radiationExperimental Dermatology, 2015
- A New Formula for Depigmenting Human SkinArchives of Dermatology, 1975